A STUDY ON THE PREVALENCE OF ADVERSE EFFECTS ASSOCIATED WITH SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR DAPAGLIFLOZIN IN A TERTIARY CARE CENTRE

ASWINI S; BABU EZHUMALAI; HANUSHA V; SETHUMEENA S

doi:10.22159/ajpcr.2024v17i12.52456

Authors

ASWINI S Department of Pharmacy Practice, C L Baid Metha College of Pharmacy, Affiliated to The Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India. https://orcid.org/0000-0002-8153-8683
BABU EZHUMALAI Department of Cardiology, Apollo Speciality Hospitals Vanagaram, Chennai, Tamil Nadu, India.
HANUSHA V Department of Pharmacy Practice, C L Baid Metha College of Pharmacy, Affiliated to The Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India
SETHUMEENA S Department of Pharmacy Practice, C L Baid Metha College of Pharmacy, Affiliated to The Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ajpcr.2024v17i12.52456

Keywords:

Sodium-glucose cotransporter 2 inhibitors, Dapagliflozin; Diabetes, Adverse effects, Urinary tract infection.

Abstract

Objectives: The objective of this study was to assess the prevalence of adverse effects associated with sodium-glucose cotransporter 2 inhibitors (SGLT2i) dapagliflozin in a real-world setting.

Methods: This observational study was conducted prospectively over 3 months in a tertiary care center in India. It focused on in-patients aged over 18 who were diagnosed with heart failure, Type 2 diabetes mellitus, or chronic kidney disease, and undergoing treatment with SGLT2i, specifically dapagliflozin, at doses of 5 or 10 mg. Patients with a glomerular filtration rate of <25 mL/min/1.73 m², pregnant or lactating women, and individuals with end-stage renal disease or undergoing dialysis were excluded from this study. Patient demographics, clinical history, and medication usage were collected using a structured pro forma.

Results: Among 60 patients, 15 (25%) experienced adverse effects. Women and those over 50 years had a significantly higher prevalence of adverse effects. The common adverse effects were urinary tract infection 5 (8.3%), urinary-like symptoms 4 (6.6%), gastrointestinal upset 3 (5%), weakness 2 (3%), and hyponatremia 1 (1.6%). The dosage (5 mg and 10 mg) was significantly associated with side effects (p<0.002). Management strategies varied, including discontinuation, temporary halting, or no change in treatment.

Conclusion: The observed higher prevalence of adverse effects in older individuals, particularly women, and with higher drug doses further emphasizes the necessity for close clinical monitoring during the initial phases of treatment.

Downloads

Download data is not yet available.

References

Hart HE, Kievits O, Rutten FH, Hollander MH. Evaluation of SGL-T2 inhibitors treatment in type 2 diabetes patients with veryhigh cardiovascular risk. Prim Care Diabetes. 2023;17(2):190-4. doi: 10.1016/j.pcd.2023.02.001, PMID: 36775727

Santulli G, Varzideh F, Forzano I, Wilson S, Salemme L, De Donato A, et al. Functional and clinical importance of SGLT2-inhibitors in frailty: From the kidney to the heart. Hypertension. 2023;80(9):1800-9. doi: 10.1161/HYPERTENSIONAHA.123.20598, PMID: 37403685

Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT, et al. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022 Jan 29;14(1):e21720. doi: 10.7759/cureus.21720, PMID: 35251794

Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: A real-world observational study. Medicines (Basel). 2022;9(12):59.

Wright EM. SGLT2 inhibitors: Physiology and pharmacology. Kidney360. 2021;2(12):2027-37. doi: 10.34067/KID.0002772021, PMID: 35419546

Gill HK, Kaur P, Mahendru S, Mithal A. Adverse effect profile and effectiveness of sodium glucose co-transporter 2 inhibitors (SGLT2i) - A prospective real-world setting study. Indian J Endocrinol Metab. 2019;23(1):50-5. doi: 10.4103/ijem.IJEM_566_18, PMID: 31016153

Ashfaq M, Shafique S, Niazi Z, Shah SY, Memon S, Qureshi K, et al. Occurence of urinary tract infections in type 2 diabetes mellitus patients taking Sodium-Glucose Co-transporter-2 (SGLT-2) inhibitors to regulate their blood sugar levels. Int J Health Sci. 2023;7(Suppl 1):1947-53. doi: 10.53730/ijhs.v7nS1.14435

Hassoun A, Dhanwal DK, Nafach J, Ajaz Y, Khan AM, Ben Nakhi A, et al. Real-world assessment of efficacy and safety parameters for dapagliflozin in management of type 2 diabetes mellitus. Dubai Diabetes Endocrinol J. 2022;28(1):25-34. doi: 10.1159/000519871

Chopra HK, Nair T, Wander GS, Ponde CK, Ray S, Khullar D, et al. Current place of SGLT2i in the management of heart failure: An expert opinion from India. J Assoc Physicians India. 2024;72(1):63-73. doi: 10.59556/japi.71.0440, PMID: 38736076

Nashar K, Khalil P. Clinical evaluation of dapagliflozin in the management of CKD: Focus on patient selection and clinical perspectives. Int J Nephrol Renovasc Dis. 2022;15:289-308. doi: 10.2147/IJNRD.S234282, PMID: 36345396

Shrikrishna A, Archana B. Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors. Afr Health Sci. 2023;23(1):270-5. doi: 10.4314/ahs.v23i1.29, PMID 37545909

Liu J, Li L, Li S, Jia P, Deng K, Chen W, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. doi: 10.1038/s41598-017-02733-w, PMID: 28588220.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27(5):473-8. doi: 10.1016/j.jdiacomp.2013.05.004, PMID: 23849632

Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-9. doi: 10.1097/MED.0000000000000311, PMID: 27898586

Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD. Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin. Nutr Diabetes. 2014;4(11):e143. doi: 10.1038/nutd.2014.40, PMID: 25365416

Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, et al. Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: Systematic review and economic evaluation. Health Technol Assess. 2018;21(2):219-20. doi: 10.3310/hta21020-c201802, PMID: 29508697

Foxman B, Somsel P, Tallman P, Gillespie B, Raz R, Colodner R, et al. Urinary tract infection among women aged 40 to 65: Behavioral and sexual risk factors. J Clin Epidemiol. 2001;54(7):710-8. doi: 10.1016/ s0895-4356(00)00352-8, PMID: 11438412

Burke KR, Schumacher CA, Harpe SE, SGLT. SGLT2 inhibitors: A systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017 Feb;37(2):187-94. doi: 10.1002/phar.1881, PMID: 27931088

Yeoh SE, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Relationship of dapagliflozin with serum sodium: Findings from the DAPA-HF trial. JACC Heart Fail. 2022;10(5):306-18. doi: 10.1016/j.jchf.2022.01.019, PMID: 35483792

Tegegne KD, Wagaw GB, Gebeyehu NA, Yirdaw LT, ShewangashawNE, Kassaw MW. Prevalence of urinary tract infections and risk factors among diabetic patients in Ethiopia, a systematic review and meta-analysis. PLoS One. 2023;18(1):e0278028. doi: 10.1371/journal. pone.0278028, PMID: 36649227